Abstract: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive malignancies with historically poor prognoses when treated with conventional chemotherapy. Romidepsin (FK228), a potent and selective class I histone deacetylase (HDAC) inhibitor, has emerged as a significant targeted epigenetic therapy for this disease. Functioning as a prodrug, romidepsin undergoes reductive activation to chelate zinc ions in the HDAC active site, leading to cell cycle arrest, apoptosis, and the degradation of critical oncoproteins. While romidepsin monotherapy has demonstrated durable clinical efficacy—earning FDA approval for relapsed or refractory PTCL—its utility is sometimes limited by hematological toxicities and the development of resistance. Current research is heavily focused on biomarker-driven patient selection, particularly for subtypes like angioimmunoblastic T-cell lymphoma (AITL) that harbor epigenetic mutations, and on synergistic combination regimens with hypomethylating agents, PI3K inhibitors, and immune checkpoint inhibitors to enhance curative potential.
1. Introduction
Peripheral T-cell lymphomas (PTCLs) represent a rare, heterogeneous, and aggressive group of non-Hodgkin lymphomas derived from mature post-thymic T cells or NK cells [20]. The standard first-line treatment for PTCL has historically relied on the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen. However, clinical outcomes with CHOP remain dismal, characterized by brief responses, high relapse rates, and a 3-year overall survival rate often falling below 30% in refractory settings [20] [71]. To address this significant unmet medical need, epigenetic therapies have been extensively investigated. Histone deacetylase inhibitors (HDACis) have emerged as a promising targeted approach capable of reversing the aberrant epigenetic silencing of tumor suppressor genes [2] [71]. Among these, Romidepsin (FK228, depsipeptide) is a potent, bicyclic class I HDAC inhibitor that received US Food and Drug Administration (FDA) approval in 2011 for the treatment of patients with relapsed or refractory (R/R) PTCL who have received at least one prior systemic therapy [3] [12].
2. Pharmacological Activity
Romidepsin has demonstrated significant single-agent pharmacological activity in R/R PTCL. In pivotal phase II clinical trials, romidepsin monotherapy achieved an objective response rate (ORR) ranging from 25% to 38%, with complete response (CR) rates of approximately 15% and a median duration of response (mDOR) reaching up to 28 months [3] [12]. A comprehensive meta-analysis of PTCL patients treated with romidepsin reported a pooled CR of 20% and a partial response (PR) of 18%, alongside a 2-year overall survival (OS) of 48% [16]. Notably, romidepsin exhibits pronounced efficacy in specific PTCL subtypes, particularly angioimmunoblastic T-cell lymphoma (AITL) and T-follicular helper cell lymphoma (T-FHCL), which are characterized by high-frequency mutations in epigenetic regulators [21].
Beyond monotherapy, romidepsin has been extensively evaluated in combination regimens. While the addition of romidepsin to CHOP (Ro-CHOP) in previously untreated PTCL did not demonstrate a statistically significant superiority over CHOP alone in a phase III trial (median progression-free survival of 12.0 vs. 10.2 months) [25] [80], other targeted combinations show marked synergy. For instance, combining romidepsin with the hypomethylating agent 5-azacytidine yielded an ORR of 76.9% in real-world R/R PTCL cohorts and up to 80% in T-FHCL specifically [5] [42]. Other promising combinations that have shown enhanced response rates in early-phase trials include romidepsin paired with pralatrexate, lenalidomide, duvelisib, and tenalisib [11].
3. Molecular Mechanism of Action
The anti-tumor efficacy of romidepsin is driven by its selective inhibition of class I HDACs, specifically HDAC1, HDAC2, and HDAC3 [3] [22] [38]. By inhibiting histone deacetylation, romidepsin promotes an open, transcriptionally active chromatin state, leading to the activation of silenced tumor suppressor genes. The key molecular mechanisms include:
Cell Cycle Arrest and Apoptosis: Romidepsin upregulates the expression of the p21 tumor-suppressor gene, which induces cell cycle arrest and subsequently triggers programmed cell death in malignant T cells [2] [3].
Protein Degradation: The drug induces the hyperacetylation of the chaperone protein HSP90. This disrupts intracellular protein homeostasis and leads to the degradation of critical oncoproteins that rely on HSP90 for stability, such as mutant p53, RAF-1, and BCR-ABL [3].
Angiogenesis Inhibition: Romidepsin downregulates angiogenic-stimulating factors like vascular endothelial growth factor (VEGF), thereby blocking endothelial cell migration, adhesion, and tumor neovascularization [3] [22].
Viral Reactivation: In Epstein-Barr virus (EBV)-positive PTCLs, romidepsin potently induces the EBV lytic cycle. This reverses cellular dedifferentiation and mediates enhanced, targeted cell death when combined with antiviral agents like ganciclovir [10] [38].
4. Structure-Activity Relationship (SAR)
Romidepsin is a natural bicyclic depsipeptide (cyclic tetrapeptide) originally isolated from the bacterium Chromobacterium violaceum [35] [47] [70]. Structurally, it functions as a prodrug. Upon entering the intracellular environment, the disulfide bond within its bicyclic structure undergoes reductive activation to form a metabolite containing a free, active thiol group [76]. This active thiol group fits precisely into the active site of class I HDAC enzymes, where it strongly chelates the critical zinc ion (Zn2+) required for catalytic activity, thereby potently and selectively inhibiting the enzyme's deacetylation function [76].
5. Current Limitations
Despite its clinical utility, romidepsin therapy is constrained by several limitations:
Toxicity Profile: Treatment is frequently associated with significant hematological adverse events (AEs), including grade 3/4 thrombocytopenia, neutropenia, and lymphopenia [3] [16]. Common non-hematological AEs include gastrointestinal issues (nausea, vomiting), fatigue, and infections [37] [63].
Combination Toxicity: When combined with standard chemotherapy (e.g., the Ro-CHOP regimen), romidepsin significantly increases the frequency of severe AEs (such as thrombocytopenia and neutropenia) without providing a marked survival advantage over CHOP alone [25] [80].
Resistance and Curative Potential: While romidepsin can elicit durable responses, it is rarely curative as a single agent. Many patients eventually develop drug resistance or experience disease relapse, necessitating further lines of therapy [2].
6. Future Perspectives
The future of romidepsin in PTCL management lies in precision medicine and rational combination strategies:
Biomarker-Driven Therapy: Genomic profiling has revealed that PTCL subtypes with mutations in epigenetic modifiers (e.g., TET2, DNMT3A, IDH2) and TCR-related genes (e.g., RHOA)—frequently seen in AITL—are particularly vulnerable to HDAC inhibition. Identifying these biomarkers will enable better patient selection and personalized treatment paradigms [5] [21] [51].
Novel Combinations: To overcome resistance and enhance efficacy, ongoing trials are investigating romidepsin in combination with other targeted agents. Synergistic regimens include combinations with hypomethylating agents (5-azacytidine), PI3K inhibitors (duvelisib, tenalisib), Aurora A kinase inhibitors (alisertib), and immune checkpoint inhibitors (pembrolizumab) [5] [11].
Optimized Delivery: Formulations such as liposomal doxorubicin combined with romidepsin are being explored to maintain anti-tumor efficacy while mitigating cardiotoxicity and other severe adverse effects [41].
